BR112013019105A2 - nanopartículas carregadas com medicamento antitumoral quimioterapêutico - Google Patents

nanopartículas carregadas com medicamento antitumoral quimioterapêutico

Info

Publication number
BR112013019105A2
BR112013019105A2 BR112013019105-8A BR112013019105A BR112013019105A2 BR 112013019105 A2 BR112013019105 A2 BR 112013019105A2 BR 112013019105 A BR112013019105 A BR 112013019105A BR 112013019105 A2 BR112013019105 A2 BR 112013019105A2
Authority
BR
Brazil
Prior art keywords
nanoparticles loaded
antitumor drug
chemotherapeutic antitumor
nanoparticles
chemotherapeutic
Prior art date
Application number
BR112013019105-8A
Other languages
English (en)
Inventor
Pisani Emilia
Lebel-Binay Sophie
Polard Valérie
Original Assignee
Bioalliance Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma filed Critical Bioalliance Pharma
Publication of BR112013019105A2 publication Critical patent/BR112013019105A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Manufacturing & Machinery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

nanopartículas carregadas com medicamento antitumoral quimioterapêutico. a invenção está relacionada a novas abordagens terapêuticas para tratamento de câncer, sobretudo carcinoma hepatocelular, com nanopartículas carregadas com um agente antitumoral quimioterapêutico. em particular, está relacionada ao tratamento de câncer por meio da administração de nanopartículas por infusão intravenosa durante um mínimo de 2 horas, a fim de evitar efeitos colaterais toxicológicos e aumentar a proporção beneficio/risco do tratamento.
BR112013019105-8A 2011-03-31 2012-03-30 nanopartículas carregadas com medicamento antitumoral quimioterapêutico BR112013019105A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305364.9A EP2508207B1 (en) 2011-03-31 2011-03-31 Nanoparticles loaded with chemotherapeutic antitumoral Drug
EP11305364.9 2011-03-31
PCT/EP2012/055756 WO2012131018A1 (en) 2011-03-31 2012-03-30 Nanoparticles loaded with chemotherapeutic antitumoral drug

Publications (1)

Publication Number Publication Date
BR112013019105A2 true BR112013019105A2 (pt) 2019-04-02

Family

ID=44513370

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013019105-8A BR112013019105A2 (pt) 2011-03-31 2012-03-30 nanopartículas carregadas com medicamento antitumoral quimioterapêutico

Country Status (26)

Country Link
US (2) US9763874B2 (pt)
EP (2) EP2508207B1 (pt)
JP (1) JP5523638B2 (pt)
KR (1) KR101578273B1 (pt)
CN (2) CN105233301A (pt)
AU (1) AU2012233666B2 (pt)
BR (1) BR112013019105A2 (pt)
CA (1) CA2822177C (pt)
CY (1) CY1117868T1 (pt)
DK (2) DK2508207T3 (pt)
ES (2) ES2424476T3 (pt)
HK (1) HK1192841A1 (pt)
HR (2) HRP20130702T1 (pt)
HU (1) HUE028465T2 (pt)
IL (1) IL227466A (pt)
ME (1) ME02470B (pt)
MX (1) MX344704B (pt)
MY (1) MY162339A (pt)
PL (1) PL2508207T3 (pt)
PT (1) PT2508207E (pt)
RS (1) RS52880B (pt)
RU (1) RU2616494C2 (pt)
SG (1) SG193453A1 (pt)
SI (1) SI2691116T1 (pt)
SM (1) SMT201600197B (pt)
WO (1) WO2012131018A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508207B1 (en) 2011-03-31 2013-05-08 BioAlliance Pharma Nanoparticles loaded with chemotherapeutic antitumoral Drug
KR102220604B1 (ko) * 2012-07-17 2021-03-02 다우 글로벌 테크놀로지스 엘엘씨 유기 액체 희석제 및 매우 낮은 점도의 셀룰로즈 에테르를 포함하는 조성물
WO2015130585A1 (en) * 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer
US20170151181A1 (en) * 2014-04-18 2017-06-01 Pfizer Inc. Methods of treating cancers with therapeutic nanoparticles
US9402834B2 (en) 2014-10-21 2016-08-02 Ions Pharmaceutical S.À R.L. Human therapeutic agents
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) * 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US9956172B2 (en) 2015-07-28 2018-05-01 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
WO2017046037A1 (en) 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
WO2017144548A1 (en) * 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and doxorubicin-loaded poly(cyanoacrylate) nanoparticles
NO342271B1 (en) * 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
CN106511365A (zh) * 2016-12-17 2017-03-22 郑州郑先医药科技有限公司 一种治疗肝硬化的西药组合物
CN111989087A (zh) * 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
MX2019015508A (es) 2019-12-18 2021-06-21 Univ Guadalajara Nanopartículas para el tratamiento del cáncer.
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310667A (en) 1976-04-22 1982-01-12 Agence Nationale De Valorisation De La Recherche (Anvar) 2-N Quaternary ammonium salt derivatives of 9-hydroxy ellipticine
FR2775435B1 (fr) 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
US7700571B2 (en) * 2002-06-05 2010-04-20 Genentech, Inc. Compositions and methods for liver growth and liver protection
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
JP5201763B2 (ja) * 2007-02-28 2013-06-05 昇一 城武 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
EP2050747A1 (en) 2007-10-12 2009-04-22 BioAlliance Pharma Dimers of harmol or of its derivatives and uses thereof
US20100234314A1 (en) * 2007-10-26 2010-09-16 Pfizer Inc. Idarubicin for the treatment of lymphoma in a dog
US20110003710A1 (en) * 2008-02-28 2011-01-06 John Hopkins University Selectin ligands useful in the diagnosis and treatment of cancer
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
EP2508207B1 (en) 2011-03-31 2013-05-08 BioAlliance Pharma Nanoparticles loaded with chemotherapeutic antitumoral Drug

Also Published As

Publication number Publication date
EP2508207B1 (en) 2013-05-08
ES2424476T3 (es) 2013-10-02
US20140024610A1 (en) 2014-01-23
JP5523638B2 (ja) 2014-06-18
PL2508207T3 (pl) 2013-09-30
MX2013007581A (es) 2013-11-01
US9763874B2 (en) 2017-09-19
WO2012131018A1 (en) 2012-10-04
CN105233301A (zh) 2016-01-13
CA2822177A1 (en) 2012-10-04
SG193453A1 (en) 2013-10-30
EP2508207A1 (en) 2012-10-10
ES2577955T3 (es) 2016-07-19
DK2691116T3 (en) 2016-07-04
HUE028465T2 (en) 2016-12-28
PT2508207E (pt) 2013-07-22
CN103379920A (zh) 2013-10-30
MX344704B (es) 2017-01-03
HRP20130702T1 (en) 2013-09-30
JP2014503577A (ja) 2014-02-13
HK1192841A1 (zh) 2014-09-05
DK2508207T3 (da) 2013-07-29
EP2691116A1 (en) 2014-02-05
KR20130114240A (ko) 2013-10-16
US20170333341A1 (en) 2017-11-23
KR101578273B1 (ko) 2015-12-16
RU2616494C2 (ru) 2017-04-17
EP2691116B1 (en) 2016-03-23
IL227466A (en) 2016-12-29
AU2012233666A1 (en) 2013-07-11
HRP20160708T1 (hr) 2016-07-15
MY162339A (en) 2017-06-15
RU2013128934A (ru) 2015-01-10
CA2822177C (en) 2016-02-16
ME02470B (me) 2017-02-20
EP2691116B8 (en) 2016-06-01
CY1117868T1 (el) 2017-05-17
AU2012233666B2 (en) 2014-01-16
SI2691116T1 (sl) 2016-10-28
IL227466A0 (en) 2013-09-30
RS52880B (en) 2014-02-28
SMT201600197B (it) 2016-08-31

Similar Documents

Publication Publication Date Title
BR112013019105A2 (pt) nanopartículas carregadas com medicamento antitumoral quimioterapêutico
PH12020500352A1 (en) Therapeutic uses of empagliflozin
NZ713868A (en) Treatment of cancer using coenzyme q10 combination therapies
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
MX346861B (es) Metodos de tratamiento de carcinoma hepato celular.
NZ717504A (en) Methods of treatment of cancer by continuous infusion of coenzyme q10
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
BR112015026292A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
MD20140123A2 (ro) Agenţi terapeutici optimizaţi pentru administrare subcutanată
NI201500100A (es) Mã‰todos de tratamiento de la deficiencia de hierro con pirofosfato fã‰rrico soluble
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
WO2012135814A3 (en) Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
WO2012158776A3 (en) Combination therapy for treatment of cancer
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
EA201590325A1 (ru) Улучшенные способы лечения рака с пониженной почечной токсичностью
LI et al. Clinicalopathological characteristics of elderly with gastric carcinoma and the risks of postoperative complications

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements